Inactive Instrument
Biodexa Pharmaceuticals Plc Stock London S.E.
Stocks
BDRX
GB00BNGF1L75
Biotechnology & Medical Research
| Market Cap | 326K 436K 389K 359K 609K 41.35M 619K 4.32M 1.71M 21.67M 1.63M 1.6M 68.31M | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 326K 436K 389K 359K 609K 41.35M 619K 4.32M 1.71M 21.67M 1.63M 1.6M 68.31M | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
0.04% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -11.76% |
| Manager | Title | Age | Since |
|---|---|---|---|
Stephen Stamp
CEO | Chief Executive Officer | 65 | 2020-03-30 |
Fiona Sharp
DFI | Director of Finance/CFO | 58 | 2026-01-04 |
Noreen Bhatti
CTO | Chief Tech/Sci/R&D Officer | - | 2024-09-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Sijmen de Vries
BRD | Director/Board Member | 67 | 2014-11-12 |
Simon Turton
BRD | Director/Board Member | 59 | 2014-12-11 |
Stephen Stamp
BRD | Director/Board Member | 65 | 2019-09-08 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -11.76% | -16.67% | - | - | 436K | |
| +2.41% | +0.29% | +39.41% | +72.14% | 64.69B | |
| -0.15% | +7.50% | +11.42% | +71.27% | 54.78B | |
| +0.57% | +4.60% | +7.71% | +90.93% | 53.49B | |
| +0.37% | +4.67% | +26.68% | +49.64% | 45.98B | |
| -1.21% | +2.32% | +21.50% | +118.33% | 42.94B | |
| -0.37% | +5.07% | +243.23% | +789.58% | 40.08B | |
| +0.05% | +0.21% | +18.06% | +48.50% | 33.52B | |
| +1.19% | -4.98% | +26.31% | -0.76% | 23.97B | |
| -0.38% | +5.68% | +38.39% | +28.35% | 23.67B | |
| Average | -0.93% | +2.41% | +48.08% | +140.89% | 42.57B | |
| Weighted average by Cap. | +0.39% | +2.73% | +46.02% | +142.84% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | - | - |
| Net Debt | - | - |
Employees
11
Calendar
Oct. 26
Significant Split/Dividend
